Loading...
•
Jun 30
Bristol-Myers Squibb Q2 2025 Earnings Report
Bristol Myers Squibb reported modest revenue growth and a decline in earnings during Q2 2025, impacted by R&D charges tied to a strategic partnership.
Key Takeaways
Bristol Myers Squibb delivered $12.3B in revenue for Q2 2025, with strength in its Growth Portfolio offset by legacy product declines. GAAP EPS dropped to $0.64 and net income declined due to a $1.5B IPRD charge related to a new partnership with BioNTech.
Total revenue reached $12.269 billion, up 1% from Q2 2024
GAAP EPS was $0.64, significantly impacted by a $1.5B acquired IPRD charge
Growth Portfolio revenue grew to $6.6B, driven by oncology drugs like Breyanzi and Camzyos
Legacy Portfolio revenue declined 14% due to generic pressure and Medicare redesign
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb Revenue by Segment
Bristol-Myers Squibb Revenue by Geographic Location
Revenue by Segment
Net Product Sales Revenue
CapyFin.comAlliance and Other Revenues Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
BMS raised its full-year revenue guidance and slightly narrowed non-GAAP EPS guidance due to strong Growth Portfolio performance and FX benefits, while accounting for the BioNTech IPRD charge.
Positive Outlook
- Revenue guidance increased to $46.5B–$47.5B
- Strength in Growth Portfolio performance
- Legacy Portfolio outperformed expectations
- Favorable $200M FX impact
- Other income raised to $250M due to better royalty and interest income
Challenges Ahead
- Non-GAAP EPS guidance lowered to $6.35–$6.65 due to IPRD charge
- R&D costs include $1.5B IPRD expense from BioNTech deal
- Gross margin slightly compressed due to product mix
- U.S. revenue declined by 3%
- Continued drag from generic competition in Legacy Portfolio
Revenue & Expenses
Visualization of income flow from segment revenue to net income